Patent SG-11201901534V-A (SG)
Title: Combination therapy with controlled-release cnp agonists
Inventor: HOLTEN-ANDERSEN LARS
IPC: A61K47/60
Filed: 2017-09-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI 0I0 11111 RH 10 011101 100 HI OM 010 IMO ill OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/060314 Al 05 April 2018 (05.04.2018) WIP0 I PCT (51) International Patent Classification: A61K 31/505 (2006.01) A61K 47/60 (2017.01) Published: A61K 38/22 (2006.01) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (21) International Application Number: PCT/EP2017/074596 (22) International Filing Date: 28 September 2017 (28.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16191456.9 29 September 2016 (29.09.2016) EP (71) Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S [DK/DK]; Tuborg Boulevard 5, 2900 Hellerup (DK). (72) Inventors: HOLTEN-ANDERSEN, Lars; Rodtjornevej _ 8, st., 2720 Vanlose (DK). MILLER BREINHOLT, Vibeke; Buen 8, 2000 Frederiksberg (DK). SPROGOE, Kennett; Vengestien 7, 2840 Holte (DK). — Agent: BUCHEL, Edwin; Isenbruck Bosl Horschler LLP = (74) Patentanwalte, EASTSITE ONE, Seckenheimer LandstraBe = 4, 68163 Mannheim (DE). Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 7r 1-1 (54) Title: COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS M 0 (57) : The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions ---- comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises GC at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the 1-1 © treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that f'1 benefits from stimulating growth. 0